Eagle Pharmaceuticals Inc (EGRX) : Jw Asset Management reduced its stake in Eagle Pharmaceuticals Inc by 11.34% during the most recent quarter end. The investment management company now holds a total of 760,379 shares of Eagle Pharmaceuticals Inc which is valued at $32.1 Million after selling 97,300 shares in Eagle Pharmaceuticals Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.Eagle Pharmaceuticals Inc makes up approximately 20.73% of Jw Asset Management’s portfolio.
Other Hedge Funds, Including , Oppenheimerfunds sold out all of its stake in EGRX during the most recent quarter. The investment firm sold 68,840 shares of EGRX which is valued $2.9 Million. Spot Trading L.l.c sold out all of its stake in EGRX during the most recent quarter. The investment firm sold 2,139 shares of EGRX which is valued $90,394.Blackrock Investment Management boosted its stake in EGRX in the latest quarter, The investment management firm added 299 additional shares and now holds a total of 29,127 shares of Eagle Pharmaceuticals Inc which is valued at $1.2 Million.Blackrock Fund Advisors boosted its stake in EGRX in the latest quarter, The investment management firm added 16,137 additional shares and now holds a total of 409,234 shares of Eagle Pharmaceuticals Inc which is valued at $17.3 Million.
Eagle Pharmaceuticals Inc opened for trading at $44.83 and hit $46.32 on the upside on Friday, eventually ending the session at $46.32, with a gain of 4.30% or 1.91 points. The heightened volatility saw the trading volume jump to 3,49,848 shares. Company has a market cap of $724,260 M.
On the company’s financial health, Eagle Pharmaceuticals Inc reported $-0.06 EPS for the quarter, beating the analyst consensus estimate by $ 0.24 according to the earnings call on May 9, 2016. Analyst had a consensus of $-0.30. The company had revenue of $29.60 million for the quarter, compared to analysts expectations of $14.26 million. The company’s revenue was down -18.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $1.31 EPS.
Many Wall Street Analysts have commented on Eagle Pharmaceuticals Inc. Shares were Reiterated by RBC Capital Mkts on May 10, 2016 to “Outperform” and Lowered the Price Target to $ 78 from a previous price target of $94 .Shares were Reiterated by Mizuho on Mar 18, 2016 to “Buy” and Lowered the Price Target to $ 71 from a previous price target of $81 .Shares were Reiterated by Mizuho on Feb 26, 2016 to “Buy” and Lowered the Price Target to $ 81 from a previous price target of $112 .
Eagle Pharmaceuticals Inc. (Eagle Pharmaceuticals) is a specialty pharmaceutical company. The Company focused on developing and commercializing injectable products. It develops products that address the shortcomings as identified by physicians pharmacists and other stakeholders of existing commercially injectable products. Its two most advanced product candidates are EP-3101 (bendamustine RTD) an intravenous version of the chemotherapeutic agent that is marketed by Teva under the brand name Treanda and Ryanodex (dantrolene for MH) and an intravenous version of an approved treatment for malignant hyperthermia. Its products include EP-3101 EP-3102 Ryanodex EP-4104 EP-6101 EP-5101 EP-1101 and EP-2101. Teva markets its bendamustine product under the trade name Treanda.